SLNO Investors Urged to Join Soleno Therapeutics Securities Fraud Lawsuit

The Schall Law Firm reminds investors of a class action lawsuit against Soleno Therapeutics for alleged violations of securities laws.

Mar. 13, 2026 at 3:29pm

Got story updates? Submit your updates here. ›

The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) for alleged violations of securities laws. The lawsuit covers the period from March 26, 2025 to November 4, 2025, and investors who purchased the company's securities during that time are encouraged to contact the firm to participate in the case.

Why it matters

This lawsuit alleges that Soleno Therapeutics made false and misleading statements to the market about the safety and commercial viability of its DCCR treatment, which could have significant financial and legal implications for the company if the allegations are proven true.

The details

According to the complaint, Soleno downplayed evidence of safety concerns revealed by its Phase 3 clinical trial of diazoxide choline extended-release tablets (DCCR). The lawsuit claims the company's DCCR treatment suffered from greater safety risks and lower commercial viability than Soleno had disclosed, and that the company's public statements were therefore false and misleading during the class period.

  • The class period covers the period from March 26, 2025 to November 4, 2025.
  • Investors have until May 5, 2026 to contact the Schall Law Firm to participate in the case.

The players

Soleno Therapeutics, Inc.

A biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.

The Schall Law Firm

A national shareholder rights litigation firm that specializes in securities class action lawsuits and shareholder rights litigation.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.”

— Brian Schall, Attorney, The Schall Law Firm (Globe Newswire)

What’s next

The judge will decide on class certification by May 5, 2026, after which investors will be represented by an attorney if they choose to join the case.

The takeaway

This lawsuit highlights the importance of transparency and accurate disclosure by pharmaceutical companies, as investors rely on this information to make informed decisions. The outcome of this case could have broader implications for the industry and set precedents around securities fraud claims.